Aurinia Pharmaceuticals (NASDAQ: AUPH) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Aurinia Pharmaceuticals to related businesses based on the strength of its earnings, analyst recommendations, valuation, profitability, dividends, institutional ownership and risk.
This is a summary of recent ratings for Aurinia Pharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aurinia Pharmaceuticals Competitors||960||3414||11919||240||2.69|
Aurinia Pharmaceuticals currently has a consensus price target of $12.00, suggesting a potential upside of 128.14%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.19%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than its peers.
Volatility and Risk
Aurinia Pharmaceuticals has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals’ peers have a beta of 2.25, indicating that their average share price is 125% more volatile than the S&P 500.
This table compares Aurinia Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aurinia Pharmaceuticals Competitors||-6,417.56%||-86.59%||-37.07%|
Insider & Institutional Ownership
28.1% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Aurinia Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aurinia Pharmaceuticals||$170,000.00||-$23.29 million||-4.35|
|Aurinia Pharmaceuticals Competitors||$290.27 million||$35.99 million||52.84|
Aurinia Pharmaceuticals’ peers have higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Aurinia Pharmaceuticals peers beat Aurinia Pharmaceuticals on 7 of the 13 factors compared.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.